Equities research analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to post $400,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for Spero Therapeutics’ earnings. The highest sales estimate is $600,000.00 and the lowest is $200,000.00. The company is expected to issue its next quarterly earnings results on Thursday, March 8th.
On average, analysts expect that Spero Therapeutics will report full-year sales of $400,000.00 for the current financial year, with estimates ranging from $1.19 million to $1.58 million. For the next year, analysts expect that the firm will report sales of $8.20 million per share. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.20 million.
Spero Therapeutics (SPRO) opened at $11.79 on Tuesday. Spero Therapeutics has a 52-week low of $9.84 and a 52-week high of $15.40.
A hedge fund recently bought a new stake in Spero Therapeutics stock. Dean Capital Investments Management LLC purchased a new stake in Spero Therapeutics Inc (NASDAQ:SPRO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 10,039 shares of the company’s stock, valued at approximately $118,000. Dean Capital Investments Management LLC owned 0.07% of Spero Therapeutics at the end of the most recent reporting period. 0.01% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/06/zacks-analysts-anticipate-spero-therapeutics-inc-spro-will-post-quarterly-sales-of-400000-00.html.
About Spero Therapeutics
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.